Login / Signup
Letter: distinct hepatitis B virus relapse rates after discontinuing tenofovir and entecavir therapy in chronic hepatitis B patients.
Rui Huang
Renling Yao
Weihua Wu
Jian Wang
Chao Wu
Published in:
Alimentary pharmacology & therapeutics (2020)
Keyphrases
</>
hepatitis b virus
end stage renal disease
ejection fraction
newly diagnosed
liver failure
chronic kidney disease
prognostic factors
peritoneal dialysis
patient reported outcomes
mesenchymal stem cells
cell therapy
liver fibrosis